© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

Equity IPOs

Top Section/Ad

Top Section/Ad

Most recent


Submarine mast maker's IPO raised €132.8m
German defence firm follows Gabler Group
Vincorion is expected to continue defence IPOs later this week
◆ How AI threat to software biz threatens stockmarket listings... ◆ ... and collaterlised loan obligation market ◆ AT1 market hits new record tight but buyers turn away
More articles/Ad

More articles/Ad

More articles

  • Mindspace Business Parks Real Estate Investment Trust has finalised the price guidance for its up to Rp45bn ($603.9m) IPO in India, set to be launched next week.
  • Boqii Co, a Chinese pet-focused e-commerce site, is working on a Hong Kong listing that could raise up to $150m, according to a source familiar with the matter.
  • Investors have got a fever, and the only cure is more pharma. Biotech equity issuance is surging, in line with rising stock prices in the secondary market, as stock pickers pan for the company that will cure Covid-19, among other maladies. But this is more speculating than investing and many are going to catch a cold chasing around a risky sector that is starting to look a lot like the dot-com bubble.
  • Ant Group, the Chinese financial technology giant behind popular mobile payments app Alipay, has set in motion plans to go public through IPOs in Hong Kong and Shanghai, in what are set to be landmark deals for Asia's equity markets.
  • Freeline Theraputics, the UK gene therapeutics company, has filed to list in the US on the Nasdaq exchange, continuing the trend of biotech companies seeking to raise capital in the equity capital markets.
  • India’s Yes Bank ended its Rp150.2bn ($2bn) share sale without enough demand to cover the deal, after a low turnout from individual investors.